Therapy Detail

Therapy Name SAR125844
Synonym
Therapy Description

SAR125844 is a selective inhibitor of MET, which inhibits MET activation and downstream pathway signaling, and potentially results in decreased growth of MET-driven tumors (PMID: 25504634).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SAR125844 MET Inhibitor 51 SAR125844 is a selective inhibitor of MET, which inhibits MET activation and downstream pathway signaling, and potentially results in decreased growth of MET-driven tumors (PMID: 25504634).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp stomach cancer sensitive SAR125844 Preclinical - Cell line xenograft Actionable In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634). 25504634
KRAS G12A MET amp lung cancer resistant SAR125844 Preclinical - Cell culture Actionable In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634). 25504634
MET amp Advanced Solid Tumor predicted - sensitive SAR125844 Phase I Actionable In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533). detail... 29145039
MET amp lung cancer sensitive SAR125844 Preclinical - Cell culture Actionable In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634). 25504634
Clinical Trial Phase Therapies Title Recruitment Status
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed